药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tazarotene
Prajmaline
The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Arsenic trioxide.
Tazarotene
Bencyclane
The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Arsenic trioxide.
Tazarotene
Cibenzoline
The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Arsenic trioxide.
Tazarotene
Gallopamil
The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Arsenic trioxide.
Tazarotene
Cicletanine
The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Arsenic trioxide.
Tazarotene
Pilsicainide
The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Arsenic trioxide.
Tazarotene
Givinostat
The risk or severity of QTc prolongation can be increased when Givinostat is combined with Arsenic trioxide.
Tazarotene
Triclabendazole
The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Arsenic trioxide.
Tazarotene
Temefos
The risk or severity of QTc prolongation can be increased when Temefos is combined with Arsenic trioxide.
Tazarotene
Tetrahydropalmatine
The risk or severity of QTc prolongation can be increased when Tetrahydropalmatine is combined with Arsenic trioxide.
Tazarotene
Delafloxacin
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Arsenic trioxide.
Tazarotene
Prulifloxacin
The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Arsenic trioxide.
Tazarotene
CUDC-907
The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Arsenic trioxide.
Tazarotene
Anisodamine
The risk or severity of QTc prolongation can be increased when Anisodamine is combined with Arsenic trioxide.
Tazarotene
Pazufloxacin
The risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Arsenic trioxide.
Tazarotene
Talinolol
The risk or severity of QTc prolongation can be increased when Talinolol is combined with Arsenic trioxide.
Tazarotene
Rupatadine
The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Arsenic trioxide.
Tazarotene
Bilastine
The risk or severity of QTc prolongation can be increased when Bilastine is combined with Arsenic trioxide.
Tazarotene
Difloxacin
The risk or severity of QTc prolongation can be increased when Difloxacin is combined with Arsenic trioxide.
Tazarotene
Sarafloxacin
The risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Arsenic trioxide.